论文部分内容阅读
本产品是近年来国际上最新开发且较成熟的正性肌力药物,主要用于充血性心力衰竭,能短期内改善心肺功能,克服了其它强心药物治疗指数低、易中毒、疗效不持久、易引起心律失常等缺点,而被认为是当前最理想、最安全、最有效的心衰治疗药物.1988年,由我厂和中国药科大学联合研制成功的该药首先在国内问世,并由我国著名心血管病专家、中国医科院阜外医院陶萍教授负责组织国内七家医院进行了二期临床验证工作.1991年底通过了卫生部审评,获新药证书及试生产批准文号.
This product is the latest internationally developed and more positive inotropic drugs, mainly for congestive heart failure, can improve heart and lung function in the short term, to overcome the other cardiac drug treatment index is low, easy to poison, the effect is not lasting , Easily lead to arrhythmia and other shortcomings, and is considered to be currently the best, most safe and most effective treatment of heart failure.In 1988, the medicine developed by our factory and China Pharmaceutical University was first developed in the country, and From China’s famous cardiovascular disease expert Fu Tao Hospital of Chinese Academy of Medical Sciences Professor Tao Ping is responsible for organizing the domestic seven hospitals for the second phase of clinical validation .1991 by the Ministry of Health review, by the new drug certificate and trial production approval number.